Advertisement
Genmab A/S

Genmab A/S (GMAB) Stock Overview

Explore Genmab A/Sā€™s financial performance, market position, analyst ratings, and future outlook.

GMABā—NASDAQ
HealthcareBiotechnology
$24.73
$0.85(3.56%)
U.S. Market opens in 16h 7m
Advertisement

Genmab A/S (GMAB)

Meyka AI Score

Z

Key Financials

Market Cap15.2B
P/E Ratio17.75
EPS (TTM)$1.31
ROE0.15%
Fundamental Analysis

AI Price Forecasts

1 Month$29.18
3 Months$29.63
1 Year Target$34.68

GMAB Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Genmab A/S (GMAB) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 31.46, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $34.68.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 17.75 and a market capitalization of 15.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
3.56%
5-Day Change
-8.24%
1-Month Change
-8.54%
3-Month Change
-12.24%
6-Month Change
-22.77%
Year-to-Date (YTD) Change
-19.71%
1-Year Change
13.54%
3-Year Change
-36.85%
5-Year Change
-39.61%
All-Time (Max) Change
555.97%

Contact Information

https://www.genmab.com
45 70 20 27 28
Kalvebod Brygge 43, Copenhagen, NaN, 1560

Company Facts

2,638 Employees
IPO DateJun 1, 2009
CountryDK
Actively Trading

Frequently Asked Questions